drugset
drugset / Trial / NCT00633269

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

NCT00633269 ↗

Phase 1 Completed 6 enrolled AstraZeneca KuDOS Pharmaceuticals Limited · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg \[14C\]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours.

Timeline

Start
2008-04
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 100 mg Oral

Indications

metastatic neoplasm